MyFinsight
Home
About
Contact
cpix: the income statement
Download
Download image
Net loss
attributable to common...
-$1,940,764
(-25.69%↓ Y/Y)
Net loss (income) at
subsidiary attributable to...
-$8,282
(-216.45%↓ Y/Y)
Net loss
-$1,949,046
(-26.81%↓ Y/Y)
Income tax expense
$5,670
(-50.45%↓ Y/Y)
Loss before income
taxes
-$1,943,376
(-27.39%↓ Y/Y)
Interest income
$131,583
(90.18%↑ Y/Y)
Product Other
$306,510
Revenues, including
adjustments-Product Redi Trex
$4,434
Revenues, including
adjustments-Product Omeclamox Pak
$600
Product Acetadote
$96,597
Product Caldolor
$867,013
Product Vibativ
$2,598,454
Product Sancuso
$3,240,947
Product Kristalose
$1,180,934
Interest expense
$109,699
(-20.15%↓ Y/Y)
Operating loss
-$1,965,260
(-15.98%↓ Y/Y)
Net revenues
$8,292,362
(-8.73%↓ Y/Y)
Revenues, including
adjustments-Product Vaprisol
-$3,127
Total costs and
expenses
$10,257,622
(-4.85%↓ Y/Y)
Amortization
$1,009,598
(-6.37%↓ Y/Y)
General and
administrative
$2,572,066
(-3.86%↓ Y/Y)
Research and development
$1,253,367
(-4.04%↓ Y/Y)
Selling and marketing
$4,433,831
(0.83%↑ Y/Y)
Cost of products sold
$988,760
(-25.26%↓ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
CUMBERLAND PHARMACEUTICALS INC (CPIX)
CUMBERLAND PHARMACEUTICALS INC (CPIX)